PIV-3 vaccine National Institutes of Health/Aviron.
Wyeth-Lederle, Aviron and NIH are developing a live intranasal parainfluenza virus (PIV) type 3 vaccine (cp45 vaccine). The vaccine is in phase II/III trials with Aviron [411386], and phase I trials with Wyeth-Lederle [408940]. It consists of a temperature-sensitive PIV-3 virus attenuated with an imported L gene mutation. This addition renders the virus 5-fold more restricted for replication in the respiratory tract of chimpanzees and also more temperature-sensitive [336999].
Jones
T
T
Intellivax International Inc, Ville St-Laurent, Quebec, Canada. tjones@intellivax.com
D000281:Administration, Intranasal; D000818:Animals; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003080:Cold Temperature; D006801:Humans; D007223:Infant; D008253:Macaca mulatta; D009154:Mutation; D009305:Nasopharynx / Q000821:virology; D002679:Pan troglodytes; D022241:Parainfluenza Vaccines / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D010224:Parainfluenza Virus 3, Human / Q000235:genetics / Q000276:immunology*; D010253:Respirovirus Infections / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D014764:Viral Proteins / Q000235:genetics / Q000378:metabolism
D022241:Parainfluenza Vaccines; D014613:Vaccines, Attenuated; D014764:Viral Proteins; C056831:parainfluenza 3 virus, L Protein